Therapy Areas
HDT Bio's COVID-19 Vaccine Approved in India
30 June 2022 - - Indian regulators have issued an Emergency Use Approval for Gemcovac, a COVID-19 vaccine based on the technology of Seattle biotech HDT Bio Corp, the company said.

The vaccine uses self-amplifying RNA, which replicates itself following administration and is thus effective at extremely low doses. In addition, it is stable at refrigerator temperatures--unlike current mRNA vaccines, which require ultra-cold storage.

With TODAY's action by Indian regulators, Gemcovac becomes the first saRNA vaccine ever approved for human use.

HDT Bio's vaccine is currently undergoing clinical trials in the US, Brazil, and South Korea.

HDT Bio is a biopharmaceutical company dedicated to providing immunotherapies to people around the world, including those in historically underserved areas.

The company seeks to harness the body's immune system to deliver therapies that narrowly target the specific areas of the body where they are needed. HDT Bio's work focuses on oncological and infectious disease applications.


Related Headlines